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Pioglitazone (Pio) is a thiazolidinedione (TZD) insulin-sensitizing drug whose effects result predominantly from its modulation of
the transcriptional activity of peroxisome proliferator-activated-receptor-gamma (PPARγ). Pio is used to treat human insulin-
resistant diabetes and also frequently considered for treatment of nonalcoholic steatohepatitis (NASH). In both settings, Pio’s
beneficial effects are believed to result primarily from its actions on adipose PPARγ activity, which improves insulin sensitivity
and reduces the delivery of fatty acids to the liver. Nevertheless, a recent clinical trial showed variable efficacy of Pio in human
NASH. Hepatocytes also express PPARγ, and such expression increases with insulin resistance and in nonalcoholic fatty liver
disease (NAFLD). Furthermore, mice that overexpress hepatocellular PPARγ and Pio-treated mice with extrahepatic PPARγ
gene disruption develop features of NAFLD. Thus, Pio’s direct impact on hepatocellular gene expression might also be a
determinant of this drug’s ultimate influence on insulin resistance and NAFLD. Previous studies have characterized Pio’s
PPARγ-dependent effects on hepatic expression of specific adipogenic, lipogenic, and other metabolic genes. However, such
transcriptional regulation has not been comprehensively assessed. The studies reported here address that consideration by
genome-wide comparisons of Pio’s hepatic transcriptional effects in wildtype (WT) and liver-specific PPARγ-knockout (KO)
mice given either control or high-fat (HFD) diets. The results identify a large set of hepatic genes for which Pio’s liver PPARγ-
dependent transcriptional effects are concordant with its effects on RXR-DNA binding in WT mice. These data also show that
HFD modifies Pio’s influence on a subset of such transcriptional regulation. Finally, our findings reveal a broader influence of
Pio on PPARγ-dependent hepatic expression of nuclear genes encoding mitochondrial proteins than previously recognized.
Taken together, these studies provide new insights about the tissue-specific mechanisms by which Pio affects hepatic gene
expression and the broad scope of this drug’s influence on such regulation.
1. Introduction
Pioglitazone (Pio) is a thiazolidinedione (TZD) agonist of the
nuclear hormone receptor (NHR) peroxisome proliferator-
activated receptor gamma (PPARγ). Pio-bound PPARγ
forms a heterodimer with retinoid X receptor (RXR [1]),
and the PPARγ-RXR complex interacts with specific peroxi-
some proliferator response elements (PPREs) in DNA to reg-
ulate metabolic and other gene expressions in adipose and
other tissues [2]. Pio has beneficial effects on insulin sensitiv-
ity and nonalcoholic fatty liver disease (NAFLD) in experi-
mental animal models [3–7], and this drug is approved for
treatment of insulin-resistant diabetes in humans [8]. Pio’s
efficacy in human nonalcoholic steatohepatitis (NASH),
which is strongly associated with insulin resistance, was
recently investigated in the “Pioglitazone versus Vitamin E
versus Placebo for the Treatment of Non-Diabetic Patients
with Nonalcoholic Steatohepatitis” (i.e. PIVENS) clinical
trial [9]. The results showed favorable Pio-induced changes
in NASH activity in some study subjects. However, most
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Pio-treated PIVENS subjects did not exhibit benefit from
that treatment. These observations implicate still-unknown
genetic and/or environmental factors as modifiers of Pio’s
physiological effects in mice and humans. Other research
has revealed tissue-specific effects of PPARγ, the canonical
target of Pio, on NAFLD in experimental models. For exam-
ple, hepatocellular PPARγ overexpression induces hepatic
steatosis [10], while liver-specific PPARγ disruption prevents
hepatic fat accumulation in mouse NAFLD models [11–13].
Conversely, muscle- [14] or adipocyte-specific PPARγ dele-
tion promotes hepatic steatosis [15], which is consistent with
the idea that PPARγ activity in adipose, and perhaps muscle,
mediates much of Pio’s efficacy towards NAFLD [16]. Other
studies show that hepatic PPARγ expression, though lower
than that of hepatic PPARα expression, is nevertheless sig-
nificantly induced in experimental and human NAFLD
[17–19]. Taken together, these considerations raise the
interesting possibility that Pio’s variable influence on
human NAFLD in the PIVENS trial [9] could have resulted
at least in part from the effects of genetic or environmental
modifiers on hepatic PPARγ expression and/or transcrip-
tional activity.
PPARγ-independent effects of Pio have also been impli-
cated as candidate mediators of Pio’s beneficial effects on
hepatic steatosis in experimental models. For example, direct
effects of this drug on the mitochondrial pyruvate carrier
protein (MPC) were recently identified as a possible contrib-
utor to Pio’s beneficial effects in NAFLD [20, 21]. Indeed,
that consideration has stimulated new interest in developing
PPARγ-sparing TZDs as novel pharmacological approaches
to human NAFLD that avoid TZD-associated side effects.
Other studies have identified beneficial effects of both Pio
and PPARγ on mitochondrial function in experimental
models of NAFLD [22] and other diseases [23]. Although
Pio’s PPARγ-dependent effects on hepatic expression of
specific adipogenic and other genes have been investigated
[10, 12, 13, 24], comprehensive assessments of such regu-
lation in general and of hepatic mitochondrial gene
expression in particular have not been reported. Moreover,
whether genetic or environmental modifiers influence such
control remains unknown. The studies reported here
address these considerations by testing the hypothesis that
diet alters Pio-induced, liver-PPARγ-dependent regulation
of hepatic gene expression and comprehensively character-
izing such regulation in mice. Our results provide new
insights into the tissue-specific mechanisms by which Pio
and hepatocellular PPARγ interact to influence hepatic
gene expression and have implications for the variable effi-
cacy Pio had in the PIVENS trial.
2. Experimental Methods
2.1. Mouse Husbandry. Liver-specific PPARγ knockout (KO)
mice were generated by breeding PPARγ-loxP mice (The
Jackson Laboratory, Bar Harbor, ME) to transgenic Alb-Cre
(B6.Cg-Tg (Alb-Cre) 21Mgn/J, The Jackson Laboratory)
mice as previously described [25]. Two-month-old male KO
or control (i.e., wildtype (WT) C57BL6/J; The Jackson Labora-
tory) mice were given ad lib access to sterile, irradiated low-fat
(S4031, BioServ, Flemington, NJ) or high-fat (S3282, BioServ;
60% kcal from fat) diets, with or without 0.01% (w/w) pioglit-
azone hydrochloride (Pio, Sigma-Aldrich, St. Louis, MO) for 3
months (n = 4 − 5mice/experimental group). Body weight
was measured weekly and body composition analyzed at the
experimental endpoint by ECHOMRI spectroscopy [26]; after
which, mice were euthanized for tissue harvest and analysis.
Blood glucose, serum insulin and free fatty acid levels, and
liver histology and triglyceride content were determined as
previously described [25–27]. All experiments were approved
by the Washington University Institutional Animal Care and
Use Committee (IACUC), and all animals received humane
care in accordance with institutional guidelines and criteria
in the “Guide for the Care and Use of Laboratory Animals”
(8th edition, 2011, https://grants.nih.gov/grants/olaw/guide-
for-the-care-and-use-of-laboratory-animals.pdf).
2.2. Hepatic Transcriptomic Analyses (RNA-Seq and RT-
qPCR). Total liver RNA was purified using the Trizol method
(Invitrogen, Carlsbad, CA). Libraries were prepared by poly-
A selection of 10μg of liver RNA using Invitrogen mRNA
Direct™ kits. mRNA was fragmented for cDNA synthesis,
which was done using Invitrogen Superscript III and random
hexamers. The cDNAs were end repaired, A-tailed, and
ligated to standard Illumina adapters. Libraries were ampli-
fied with primers to incorporate a unique index into each
sample. RNA-seq reads were aligned to the Ensembl release
76 GRCm38 assembly with STAR version 2.0.4b. Gene
counts were derived from the number of uniquely aligned
unambiguous reads by Subread:featureCount version 1.4.5.
All gene-level counts were then imported into R version
3.4.1, and TMM normalization size factors were calculated
to adjust samples for differences in library size with the Bio-
conductor package EdgeR version 3.20.2. Genes expressed
less than 1 count per million in less than 5 samples, and ribo-
somal genes were excluded from further analysis. The TMM
size factors and the matrix of counts were then imported into
the R/Bioconductor package Limma version 3.34.4 [28, 29],
and weighted likelihoods based on the observed mean-
variance relationship of every gene were then calculated for
all samples with the voomWithQualityWeights function.
Performance of the samples was then assessed with Spear-
man correlation matrix multidimensional scaling plots and
principal component analysis. Gene performance was
assessed with plots of residual standard deviation of every
gene to their average log-count with a robustly fitted trend
line of the residuals. Generalized linear models with robust
dispersion estimates were then created to test for gene/tran-
script level differential expression. Differentially expressed
genes and transcripts were then filtered for FDR adjusted
p values of q ≤ 0:05 [30, 31]. To enhance the biological
interpretation of the large set of transcripts, the filtered
gene lists were interrogated for overrepresentation of Hall-
mark gene sets using the hypergeometric tests available
through the Broad Institute’s Molecular Signature Database
(http://software.broadinstitute.org/gsea/msigdb/annotate.jsp
[32, 33],). Perturbations in expression across these gene sets
versus the background gene signals were assessed with the R
package Gage version 2.28.0.
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Hepatic expression patterns of some of the genes identi-
fied as differentially expressed by RNA-Seq were confirmed
using real-time semiquantitative RT-PCR (RT-qPCR) analy-
ses as described previously [27] together with the oligonucle-
otide primers listed in Supplementary Table S1.
2.3. RXR Chromatin Immunoprecipitation (ChIP) with High
Throughput DNA Sequencing (Seq). RXR ChIP-Seq was
conducted using an approach analogous to the one previ-
ously employed for acetyl-histone ChIP-Seq [27, 34].
Briefly, frozen liver was minced, crosslinked in 1% formal-
dehyde, homogenized, and suspended in nuclear lysis buffer
in the presence of protease inhibitors, then centrifuged to
recover chromatin, which was sheared in a Bioruptor Soni-
cator (Diagenode, Denville, NJ) to generate uniform 100-
500 base pair (bp) fragments. Equal quantities of chromatin
(based on protein content) were immunoprecipitated using
a ChIP-grade anti-RXRα/β/γ antibody (sc-774; Santa Cruz
Biotechnology, Inc., Beverly, MA) previously validated and
used in RXR ChIP-Seq studies of liver tissue [35, 36]. The
studies reported here adhered to the guidelines and prac-
tices recommended for analyses and quality control of
ChIP-Seq data by the Encyclopedia of DNA elements (i.e.,
ENCODE and modENCODE) consortia guidelines [37].
These include recommendations to validate the specificity
of the ChIP target transcription factor antibody by immu-
noblot (Supplementary Figure S1) and to assess each
replicate of immunoprecipitated chromatin for quality
metrics including NSC, RSC, Qtag score, and Irreproducible
Discovery Rate (IDR) data. As described in Supplementary
Materials, assessment of those metrics here met ENCODE
guidelines’ criteria (as described in detail in the Supporting
Information). Of note, the replicate livers studied here came
from separate animals as opposed to the independent cell
cultures, embryo pools, or tissue sampling that account for
most substrates of the ENCODE experiments. Based on that,
we anticipated the possibility of increased variability when
considering experimental design, which prompted us to use
liver samples from each of 5 mouse replicates per group,
retain all replicates for these analyses, and apply the
additional stringencies to data analysis described below.
Immunoprecipitated DNAs and corresponding input
samples were submitted to the WU GTAC for blunt ending,
adaptor ligation, size selection, and amplification according
to established protocols and as previously described [27,
34]. Libraries were sequenced using the Illumina HiSeq-
3000 as single 50 bp reads. Raw data were demultiplexed
and aligned to the most recent mouse reference genome
assembly (i.e., mm10) using Novoalign (Novocraft; Selangor,
Malaysia). Sequence peaks were identified by comparing data
from the anti-RXR antibody immunoprecipitated samples to
corresponding inputs for each replicate using MACS2 [38].
Peaks were associated to genes using Peak Annotation and
VISualization (PAVIS) software [39]. Significant differences
in gene-associated peak sequence abundances between
experimental groups were determined using DiffBind, an
open source Bioconductor package that utilizes edgeR soft-
ware for statistical analysis of replicated sequence count data
[30, 31]. These analyses used a Benjamini and Hochberg false
discovery rate (FDR) threshold of q < 0:05 [40, 41]. We also
applied the following additional stringencies: (i) ≥2-fold
change in RXR liver-DNA binding between experimental
groups as defined by DiffBind and (ii) identification of the
gene-associated RXR-bound peak by MACS in at least 3
(out of the 4-5) replicates in each experimental group with
increased binding. Gene set overrepresentation analysis was
conducted on genes differentially bound by RXR using the
approach described for RNA-Seq data analyses.
Efforts to conduct PPARγ ChIP-Seq analyses on these
liver samples were also attempted here, but those efforts were
unsuccessful based on inability to identify a PPARγ antibody
meeting the ENCODE guidelines when tested on mouse liver
(as summarized above and described in detail in the Support-
ing Information; S. Kulkarni, J. Huang, and D.A. Rudnick,
unpublished observations). Therefore, in order to assess the
liver PPARγ-dependence of RXR liver DNA binding in the
samples studied here, RXR-ChIP-Seq studies were conducted
on livers from WT and liver-specific PPARγ KO mice and
the result compared.
2.4. Venn Diagram Analyses and Binding and Expression
Target Analysis (BETA). Interactivenn [42]) was used to
determine and illustrate overlaps between genes identified
as differentially expressed or differentially RXR-bound
between groups. RXR ChIP-Seq and RNA-Seq datasets were
also compared using “Binding and Expression Target Analy-
sis” (BETA) software [43]. BETA is a publicly available soft-
ware package that integrates ChIP- and RNA-Seq data to
infer the function of a cis-acting regulator (in this case
RXR-DNA binding as defined by ChIP-Seq data) on gene-
specific patterns of expression (as defined by RNA-Seq data).
Here, RXR-ChIP-Seq-defined peaks identified as differen-
tially RXR-bound between groups (q < 0:05) were entered
into the BETA algorithm (as a bed file using the format: chro-
mosome number, chromosome start locus, and chromosome
end locus). Differential gene expression data, extracted from
the RNA-Seq data analysis, was provided to the software (as a
tab-delimited text file using the format: gene ID, expression
change, and FDR). The BETA algorithm assigned a rank
and rank-product to each gene, with higher ranks and lower
rank-products corresponding to genes whose change in
expression is more likely to be regulated by the transcription
factor-DNA binding event. Inferences about the effects of
Pio, hepatic PPARγ expression, and HFD exposure on
RXR-dependent liver gene expression were made based on
comparisons between experimental groups.
2.5. Statistical Analysis. ChIP- and RNA-Seq datasets were
analyzed as described above. All other data were analyzed
using SigmaPlot 13.0 (Systat Software Inc., San Jose, CA).
Numerical data comparisons between groups were made
using unpaired two-tailed Student’s t-test for pair-wise com-
parisons and ANOVA for multiple groups. Secondary post
hoc comparisons were conducted using Holm-Sidak for nor-
mally distributed data or Tukey for data that was not normally
distributed. Chi-squared analysis was used to compare rates
and proportions between groups. Significance (alpha) was set
at 0.05. Data are reported as mean ± standard error.
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3. Results
3.1. Pio Has Distinct Effects on Mouse Metabolism in WT
versus Liver-Specific PPARγ KO Mice Given Control versus
HFD. Unsupplemented- or Pio-supplemented-control (i.e.,
“control” or “Pio”) or high-fat (i.e., “HFD” or “HFD-Pio”)
diets were given to male WT and liver-specific PPARγ KO
mice from age 2 to 5 months. Initial body weights were com-
parable between treatment groups (i.e., ±Pio, ±HFD) but sig-
nificantly greater in 2-month-old WT versus age-matched
KO mice (Supplementary Figure S2). By the experimental
endpoint, 5-month-old WT mice exposed to Pio, HFD, or
HFD-Pio showed significantly greater weight gain and body
fat mass fractions compared to controls (Figures 1(a)–1(d)).
In contrast, KO mice displayed only limited changes in
weight and no change in percent body fat mass in response
to either intervention. Consistent with those findings, lean
mass, fat mass, and percent fat mass were also significantly
higher in HFD and HFD-Pio-treated WT mice compared
to the corresponding KOs. Nonfasting a.m. serum insulin
and blood glucose levels were comparable across all



































































































































































































































































Figure 1: Effects of Pio on WT and PPARγ KO mice. (a) Weight (indexed to initial weight), (b) lean mass (g), (c) fat mass (g), (d) fat mass
(expressed as fraction of total mass), (e) serum insulin (mIU/mL, nonfasting a.m.), (f) blood glucose (mg/dL, nonfasting a.m.), (g) serum free
fatty acids (FFA) (mM, nonfasting a.m.), and (h) liver triglycerides (mg/g liver) in wildtype (WT) and liver-specific PPARγ knockout (KO)
mice given a control or high-fat diet (HFD) unsupplemented or supplemented with Pioglitazone (Pio). ∗p < 0:05 vs. corresponding control
diet-treated group; ∧p < 0:05 vs. corresponding Pio-treated group; ∗∗p < 0:05 vs. all other WT groups; #p < 0:05 vs. corresponding HFD-
treated group; &p < 0:05 vs. corresponding WT group.
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mice displayed increased serum-free fatty acids (FFA’s)
compared to control and Pio-treated WT mice, while
control and Pio-treated KO mice exhibited increased serum
FFA’s compared to the corresponding WT animals
(Figure 1(g)). Finally, the effects of both Pio and diet on
liver triglyceride content and hepatic steatosis varied
depending on hepatocellular PPARγ expression: Pio increased
liver fat content in WT mice on control diet but decreased
these measures in the corresponding KO mice, and HFD-
exposed KO mice displayed reduced liver triglycerides and
less hepatic steatosis than the corresponding WT mice
(Figures 1(h) and 2). Taken together, these data reveal
distinct hepatic and systemic metabolic responses to Pio in
the absence versus the presence of HFD and define the
hepatocellular PPARγ dependence of those effects.
3.2. Diet Modifies Some of the Effects of Pio on Hepatic Gene
Expression. Next, Pio’s influence on genome-wide patterns
of hepatic gene expression in WT mice on control or HFD
was determined, with those results compared to correspond-
ing analyses of the liver-specific PPARγ KO mice. First, to
establish the validity of this approach, these transcriptomic
data were first inspected for patterns of Pio-induced,
PPARγ-dependent changes in hepatic expression of canoni-
cal adipogenic and lipogenic genes whose PPARγ-regulated
hepatic expression has previously been reported [10, 12, 13,
24]. Consistent with such published data, the transcriptomic
data reported here show Pio-induced hepatic expression of
Caveolin 1 (Cav1), Cd36, Complement factor D (Cfd, also
known as Adipsin), Cidec (also known as Fsp27), Fabp4
(also known as Ap2), Mogat1, and Plin4 (also known as
S3-12) in WT but not KO mice on control diet
(Figure 3(a)). Further analyses also showed that Pio induces
Cd36, Cfd, Cidec, Mogat1, and Plin4 but not Cav1 or Fabp4
in WT mice on the HFD. As for mice on the control diet,
Pio also had no significant effects on expression of these
genes in HFD-treated KO mice (Figure 3(b)). Finally, to
further validate our transcriptomic data, the RNA-Seq
based results depicted in Figure 3 were compared to RT-
qPCR based analyses of differential expression between
groups in these exemplar genes, with the results of the latter
studies (Supplementary Figure S3) highly concordant with
those of the former (Figure 3). These data are consistent
with previously published analyses of PPARγ-dependent
hepatic transcriptional effects, and they implicate diet as a
specific modifier of those effects.
Next, these transcriptomic data were subjected to prin-
ciple component analysis (PCA). The results showed excel-
lent segregation of replicates of WT mice by exposure to
drug (±Pio) and diet (±HFD) (Figure 4(a)). In contrast,
the corresponding KO replicates showed poor separation
(Figure 4(b)). Similarly, heat map analyses of Pio-
induced changes in hepatic gene expression also showed
more faithful segregation of the WT versus the KO experi-
mental replicates (Figures 4(c) and 4(d)). Consistent with
the exemplar gene expression data in Figure 3, Venn dia-
gram analyses of patterns of overlap in these data identified
subsets of genes whose Pio-induced hepatic expression is
concordantly regulated in WT mice on control or HFD,
and others whose Pio-induced regulation is altered by
HFD (Figure 4(e)). This analysis also revealed a lack of
concordance between the hepatic transcriptional effects of
Pio in KO mice on control versus HFD and, furthermore,
that Pio has no significant effects on hepatic gene expres-
sion in KO mice on HFD (Figure 4(f)). The results of the
converse analyses, comparing the influence of diet on mice
with or without Pio exposure, provide further support for
the modifying influence of diet on Pio-induced changes in
hepatic gene expression (Figures 4(g) and 4(h)). Taken
together, these data reveal interactions between diet and
hepatocellular PPARγ expression that influence Pio-
induced changes in hepatic gene expression.
To further explore dietary influences on Pio-regulated
changes in hepatic gene expression, those genes identified
as differentially expressed in the studies summarized in
Figure 4 were subject to gene set overrepresentation analysis
using the Hallmark gene set database, on the Broad Institute
platform (http://software.broadinstitute.org/gsea/msigdb/
annotate.jsp [32, 33],), and the most stringent FDR threshold
cutoff on that platform (i.e., q < 1e−6). This evaluation identi-
fied significant enrichment of genes induced by Pio in livers
from WT mice on the control diet for those associated with
metabolic and other functional categories (Table 1(a)). The
most highly enriched of those groupings, fatty acid metabo-
lism, adipogenesis, and bile acid metabolism, were also iden-
tified as enriched for genes induced by Pio inWTmice on the
HFD (Table 1(b)). However, this analysis also revealed dis-









H&E stained liver sections
HFD-Pio
Figure 2: Effects of Pio on WT and KO mouse liver histology. H&E -stained liver sections from control diet (Control)-, Pio-, high-fat diet
(HFD)-, or HFD and PIO (HFD-Pio)-treated mice. 500 micron bar shown in lower left corner.
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control versus HFD, including specific enrichment of genes
associated with cholesterol homeostasis in livers from mice
on the control but not the HFD diet, and of glycolysis in
mice on HFD but not control diet (Table 1(a) and (b)).
These transcriptomic data were also subjected to GAGE
analysis for gene set level changes in expression, and the
results of that independent assessment of these data are
highly concordant with those of the gene set overrepresen-
tation study (Supplementary Table S3). For example, the
GAGE examination also identified enrichment of Pio-
induced genes associated with fatty acid metabolism,
adipogenesis, and bile acid metabolism in mice on either
diet, but specific enrichment for cholesterol homeostasis
genes in mice on the control diet and for glycolysis genes
in mice on the HFD. Genes whose hepatic expression is
suppressed by Pio in WT mice were similarly assessed
and also showed marked differences between control and
HFD-treated mice. For example, those suppressed by Pio
in WT mice on control diets are enriched in many
different categories, including UV response up and heme
metabolism, while those suppressed by Pio in mice on
HFD were not significantly enriched for any gene
categories when analyzed in this way (Table 1C and D).
As for Pio-induced genes, the results of GAGE-based
investigation of these data are also quite concordant with
gene set overrepresentation analyses (Supplementary
Table S3). Similar hepatic transcriptomic investigations of
liver-specific PPARγ KO mice, using gene set over-
representation- and GAGE-based analyses, identified
distinct dietary effects on patterns of Pio-induced and Pio-
suppressed genes in these compared to WT mice (Table 2
vs. Table 1 and Supplementary Table S3). In this case, gene
set overrepresentation analyses showed that Pio’s
suppressive effects on hepatic gene expression in KO mice
on control diet and its inductive and suppressive effects in
KO mice on HFD are virtually undetectable (Table 2B–D).
Converse analyses, of the influence of diet in the absence or
presence of Pio, showed a greater range of dietary influence
in Pio-treated compared to untreated WT mice and
markedly fewer effects of diet on the KO mice (Figures 4(g)
and 4(h) and Supplementary Tables S4 and S5). Taken
together, these data provide evidence for the modifying
influence of diet on PPARγ-dependent, Pio-induced
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Figure 3: Effects of Pio on hepatic expression of exemplar genes. Summary of RNA-Seq data of exemplar genes whose expression is known to
















































































































3.3. PPARγ-Dependent Effects of Pio and HFD on Liver RXR-
DNA Binding Are Highly Concordant with Corresponding
Effects on Hepatic Gene Expression. To further characterize
Pio’s direct effects on hepatic transcriptional regulation, the
consequences of Pio and HFD on gene-specific RXR-
binding to liver DNA inWT and KOmice were characterized
and compared by RXR-chromatin-immunoprecipitation
combined with next-generation DNA sequencing (ChIP-
Seq). The results identified specific RXR-DNA binding sites
in both untreated and Pio-treated WT mice on either a con-
trol or HFD. They also revealed Pio-induced differences in
such binding at some of those sites. In most cases, Pio
increased RXR-DNA binding, but sites whose RXR-DNA
binding is suppressed by Pio were also identified
(Figures 5(a)–5(c)). This analysis also showed that Pio has
broader effects on gene-specific RXR-liver DNA binding in
WT mice on the control versus the HFD, with most binding
sites identified in HFD-treated mice also identified in mice
on the control diet but many binding sites detected in mice
on the control diet not detected in those on the HFD
(Figure 5(d)). Thus, these data provide further evidence for
the modifying influence of diet on Pio-induced hepatic
transcriptional regulation, and they implicate diet-induced
differences in Pio’s direct effects on liver RXR-DNA bind-
ing as a contributing mechanism. More than half of the
Pio-induced RXR-liver DNA binding sites detected in
WT mice on either diet occurred within exons or introns
of specific genes, with binding to 5′ or 3′ untranslated
regions (UTRs), upstream, downstream, or other sites
accounting for the rest of such binding (Figure 5(e)).
While parallel analyses of the KO mice also identified
RXR-liver DNA binding sites (Figure 5(f)), in this case,
very few sites with significant (i.e., q < 0:05) Pio-induced
changes in RXR binding were identified (Figure 5(g)). Fur-
thermore, most of those sites showed Pio-inhibited bind-
ing (Figure 5(g)) and none withstood the additional
stringencies of our analytical approach (Figure 5(h) and
Experimental Methods). Further analyses of HFD effects
on such regulation identified a small number of differen-
tially bound genes in WT mice in the absence of Pio
and none in WT mice in the presence of Pio or in KO
mice with or without Pio (data not shown). Together,
these data define Pio’s PPARγ-dependent effects on induc-
tion of gene-specific RXR-liver DNA binding in mice on
either diet. They also reveal that HFD exposure blunts
the effects of Pio on such transcriptional regulation.
Next, gene set hypergeometric tests were performed on
genes exhibiting Pio-induced RXR-liver DNA binding in
WT mice fed either the control (Table 3A) or HFD
(Table 3B). The results showed enrichment in many of the
same categories identified by analyses of Pio-induced
(Table 1A and B) or Pio-suppressed (Table 1C and D)
hepatic gene expression. These observations imply that
Pio-induced changes in RXR-liver DNA binding are
transcription-inducing in some cases and transcription-
suppressing in others. However, some categories enriched
for genes whose expression is induced (i.e., in Table 1) were
not similarly identified by these analyses of RXR-liver DNA
binding (i.e., in Table 3A and B), including bile acid metabo-
lism and cholesterol homeostasis. Presumably, this finding
results from transcription-altering influences of Pio on
hepatic gene expression (in Table 1A and B) that are inde-
pendent of hepatocellular PPARγ expression, hepatic RXR
activity, or both. For example, recently described direct
effects of Pio on the mitochondrial pyruvate carrier protein
activity [20, 21] might have indirect transcriptional conse-
quences. Conversely, other categories identified as enriched
for RXR-bound genes in Table 3A and B were not identified
by the gene set analysis of RNA-Seq data in Table 1, includ-
ing glycolysis and unfolded protein response, and the signif-
icance of RXR-binding to those gene sites with respect to
transcriptional regulation is uncertain. Finally, these studies
did not identify any categorical gene set enrichment amongst






















































Figure 4: Effects of Pio on the hepatic transcriptome. (a, b) Principle component (PCA) and (c, d) heat map analyses of differentially
expressed genes from RNA-Seq analyses of livers from (a, c) WT or (b, d) KO mice treated with control diet, Pio, HFD, or HFD and Pio.
Heat map analyses are based on Pio-induced differences in gene expression. (e–h) Venn diagrams (generated using InteractiVenn [42])
depict overlap between differentially expressed genes by treatment group in WT (e, g) or KO (f, h) mice.
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binding (Table 3C and D), nor did they demonstrate any
Pio- or HFD-induced differences in such binding in the
KO mice (Table 3E–H). When taken together, these data
reveal a high overall degree of concordance between
PPARγ-dependent and Pio-induced effects on RXR-liver
DNA binding to and differential hepatic expression of
specific genes, and they further implicate diet as a modifier
of that regulation.
Table 1: Gene set analysis∗ on RNA-Seq data from WT Pio-treated vs. Pio-untreated mice on control or HFD (as designated).
Gene set name (# in Hallmark set) Description Overlap q value
(a) Induced by Pio in WT mice on control diet
FATTY_ACID_METABOLISM [158]
Genes encoding proteins involved in
metabolism of fatty acids.
51 4.84e-33
ADIPOGENESIS [200]




Genes involve in metabolism of bile
acids and salts.
30 3.36e-17
CHOLESTEROL_HOMEOSTASIS [74] Genes involved in cholesterol homeostasis. 22 7.81e-14
OXIDATIVE_PHOSPHORYLATION [200]
Genes encoding proteins involved in
oxidative phosphorylation.
32 9.78e-12
PEROXISOME [104] Genes encoding components of peroxisome. 21 7.38e-10
UV_RESPONSE_DN [144]








Genes upregulated in response to
IFNG (GeneID=3458).
26 6.74e-8
(b) Induced by Pio in WT mice on HFD
FATTY_ACID_METABOLISM [158]
Genes encoding proteins involved in
metabolism of fatty acids.
32 1.32e-28
OXIDATIVE_PHOSPHORYLATION [200]




Genes upregulated during adipocyte
differentiation (adipogenesis).
32 1.13e-25
PEROXISOME [104] Genes encoding components of peroxisome. 20 7.76e-18
BILE_ACID_METABOLISM [112]
Genes involve in metabolism of
bile acids and salts.
14 5.33e-10
GLYCOLYSIS [200]
Genes encoding proteins involved in
glycolysis & gluconeogenesis.
14 8.69e-7
(c) Suppressed by Pio in WT mice on control diet
UV_RESPONSE_UP [158] Genes upregulated in response to UV radiation. 35 9.3e-16
HEME_METABOLISM [200]




Genes upregulated through activation of
mTORC1 complex.
28 3.4e-8
P53_PATHWAY [200] Genes involved in p53 pathways and networks. 28 3.4e-8
APOPTOSIS [161] Genes mediating apoptosis by activation of caspases. 24 8.69e-8
HYPOXIA [200] Genes upregulated in response to low oxygen levels. 27 8.69e-8
DNA_REPAIR [150] Genes involved in DNA repair. 23 8.69e-8
XENOBIOTIC_METABOLISM [200]
Genes encoding proteins that process
drugs & other xenobiotics.
26 2.71e-7
UNFOLDED_PROTEIN_RESPONSE [113]




A subgroup of genes regulated by
MYC - version 1 (v1).
25 9.04e-7
(d) Suppressed by Pio in WT mice on HFD
No overlaps found
∗Using the Broad Institute platform with the Hallmark gene sets platform to identify the top 10 categories with p ≤ 1e−6 (see text for details).
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3.4. Integrating Pio’s Influences on Liver RXR-DNA Binding
and Hepatic Transcription. Finally, to further characterize
and clarify the impact of diet on Pio-induced, PPARγ-depen-
dent hepatic transcriptional regulation, the RNA- and ChIP-
Seq datasets generated in these studies were compared to
each other using the “Binding and expression target analysis”
(BETA [43],) algorithm. This analytical tool was developed to
infer target gene regulation by specific transcription factors.
The results here identified 760 genes bound by RXR and
induced by Pio and 1066 RXR-bound genes suppressed by
Pio in WT mice on control diet, and 420 induced and 531
suppressed RXR-bound gene targets of Pio in WT mice on
HFD (Figure 6(a)). Most genes identified by this analysis as
induced or suppressed by Pio in mice on the control diet were
not similarly identified in mice on the HFD (Figure 6(a)).
However, gene set over-representation analysis did demon-
strate high concordance between the categorical terms iden-
tified as enriched for RXR-bound genes induced by Pio on
control or HFD. Those categories include Oxidative phos-
phorylation, Fatty acid metabolism, and Myc targets
(Table 4A and B). Further inspection of the specific Pio-
regulated genes enriched in these sets revealed an abundance
of nuclear genes encoding mitochondrial proteins involved
in oxidative phosphorylation. Those genes include compo-
nents of complexes I-IV, and the mitochondrial ATP syn-
thase, as well as transporters, ion channels, enzymes
involved in TCA cycle, and other outer membrane, inter-
membrane space, inner membrane, and matrix mitochon-
drial proteins (Figure 6(b)). Moreover, almost all of the
specific mitochondrial protein-encoding genes identified in
this way that were induced in mice on the control diet were
not induced in mice on the HFD, and, conversely, most of
those induced in HFD-treated mice were not similarly upreg-
ulated in mice on the control diet. Thus, this analysis also
demonstrates that diet induces unique changes in Pio’s spe-
cific transcriptional effects on nuclear genes encoding mito-
chondrial proteins. Gene set over-representation analysis
on RXR-bound genes suppressed by Pio inWTmice was also
conducted, with the results showing no overlap between
functional categories enriched in suppressed genes frommice
on control versus those on HFD. For example, genes associ-
ated with Unfolded protein response were enriched amongst
those suppressed by Pio in WT mice on the control diet but
not the HFD (Table 4C and D). These results provide further
evidence for the modifying influence of diet on Pio’s hepatic
transcriptional effects. Finally, the differences in RXR liver
DNA binding detected in the KO mice were insufficient to
permit the corresponding BETA analysis on these data
(Figure 5(g) and 5(h)).
4. Discussion
Previously published studies have reported PPARγ-depen-
dent effects of TZDs on the hepatic expression of individual
Table 2: Gene set analysis∗ on RNA-Seq data from Pio-treated vs. Pio-untreated KO mice on control or HFD (as designated).
Gene set name (# in Hallmark set) Description Overlap q value
(a) Induced by Pio in KO mice on control diet
CHOLESTEROL_HOMEOSTASIS [74] Genes involved in cholesterol homeostasis. 20 1.04e-18
ESTROGEN_RESPONSE_LATE [200] Genes defining late response to estrogen. 22 3.64e-12
TNFA_SIGNALING_VIA_NFKB [200]








Genes mediating apoptosis by
activation of caspases.
18 1.83e-10
ESTROGEN_RESPONSE_EARLY [200] Genes defining early response to estrogen. 19 7.36e-10
NOTCH_SIGNALING [32]












Genes upregulated during adipocyte
differentiation (adipogenesis).
15 9.91e-7
(b) Induced by Pio in KO mice on HFD
No significantly differentially expressed genes
(c) Suppressed by Pio in KO mice on control diet
XENOBIOTIC_METABOLISM [200]
Genes encoding proteins that process
drugs and xenobiotics.
24 2.13e-13
(d) Suppressed by Pio in KO mice on HFD
No significantly differentially expressed genes
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target genes of interest by comparing the hepatic expression
of those specific genes in WT versus PPARγ-overexpressing
or liver-specific PPARγ KO mice [10, 12, 13, 24]. Such stud-
ies, which were recently reviewed [44], show that hepatic
PPARγ expression regulates the expression of adipogenic
genes in the liver and also modulates extrahepatic lipid accu-
mulation and insulin sensitivity. Nevertheless, the studies
reported here are the first to comprehensively characterize
such transcriptional regulation (by RNA-Seq), compare the
results to genome-wide assessment of PPARγ-dependent,
Pio-induced effects on liver RXR-DNA binding (with ChIP-
Seq), and integrate those datasets (with BETA). The results
show (i) Pio’s liver-PPARγ-dependent hepatic transcrip-
tional effects are highly concordant with its effects on liver
RXR-DNA binding in WT mice on either diet. (ii) HFD
modifies Pio’s influence on such transcriptional regulation.
(iii) Pio has a much broader influence on PPARγ-dependent
hepatic expression of nuclear genes encoding mitochondrial
proteins than has previously been reported. These data pro-
vide new insights into the molecular and cellular mecha-
nisms by which Pio and hepatocellular PPARγ interact to
influence hepatic gene expression. They also raise the possi-
bility that diet is a modifier of Pio’s efficacy in human
NAFLD. Such efficacy was variable amongst subjects enrolled
in the PIVENS trial [9]. Consistent with previously published
work [10–13], our data also show that (i) hepatocellular
PPARγ overexpression induces hepatic steatosis. (ii)
Liver-specific PPARγ disruption protects mice from
HFD-induced NAFLD. (iii) TZD administration (Pio here)
stimulates hepatic fat accumulation in WT but not liver-
specific PPARγ-KO mice. Other studies have also shown
that extrahepatic tissue-specific (i.e. muscle- [14] or adipo-
cyte- [15]) PPARγ deletion promotes NAFLD and that
TZD-treatment exacerbates fatty liver disease in muscle-
specific PPARγ KO mice [14]. Taken together, our data
and these considerations are also consistent with the pos-
sibility that variable responses to Pio in human NAFLD
might be determined, at least in part, by the balance
between TZD effects on hepatic versus extrahepatic (i.e.,
adipose or perhaps skeletal muscle) PPARγ activity.
The studies here are the first to compare Pio-induced
changes in the liver RXR cistrome and hepatic transcriptome
with the hepatocellular PPARγ dependence of those changes.
Nevertheless, similar analyses of other RXR-binding,
metabolic-sensing nuclear hormone receptors (NHRs) have
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(h)
Figure 5: Effects of Pio on the hepatic RXR cistrome. (a) Total RXR-DNA binding sites (by group), (b) Volcano plots comparing differential
RXR-DNA binding in replicate livers from Pio- versus Control- or HFD-Pio- versus HFD-treated groups of mice, and (c) Total (and unique)
DNA sites with significantly different RXR-DNA binding (between groups), each defined as described in Experimental methods. (d) Venn
diagram of overlap between sites of significant Pio-induced RXR-liver DNA binding in mice on control versus HFD. (e) Pie chart
illustration of the locations of sites for genes summarized in (d) with respect to gene-specific transcription start sites in control versus
HFD mice. (f–h) Results of corresponding RXR-liver DNA binding ChIP-Seq analyses of liver-specific PPARγ KO mice.
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receptor (FXR) agonist obeticholic acid on FXR-DNA bind-
ing and gene expression in human and mouse liver tissue
were recently reported [45]. The availability of that published
data permitted us to compare and contrast genes whose
expression was significantly induced or suppressed by obeti-
cholic acid in that study to those identified here as regulated
by Pio in WT mouse liver. The results show distinct hepatic
transcriptional effects of the FXR agonist (obeticholic acid)
in that study versus those of the PPARγ agonist (Pio) studied
here (Figure 7(a)). Another recent study reported the RXR-
liver DNA binding effects of a liver X receptor (LXR) agonist
(i.e., T0901317 [35]). We also compared those published data
to our characterization of Pio-induced gene-specific RXR-
liver DNA binding here. That analysis also shows very little
overlap between the T0901317- and Pio-induced RXR-
DNA binding signatures (Figure 7(b)). These results are con-
sistent with the idea that specific pharmacological agonists of
different metabolic-sensing NHRs (e.g., Pio/PPARγ, obeti-
cholic acid/FXR, and T0901317/LXR) induce distinct effects
on RXR-liver DNA binding and hepatic transcriptional regu-
lation. That conclusion raises the possibility, also implicated
by other studies [35, 46–48], that “cross-talk” in RXR-
binding to different NHRs is an important determinant of
NHR-ligand effects on gene expression patterns. These con-
siderations are also consistent with the idea that drugs with
distinct NHR-binding activities compete with each other
and endogenous NHR ligands to exert unique effects on
RXR-dependent transcriptional regulation. That concept,
illustrated by the hypothetical model in Figure 7(c), raises
the additional consideration that specific combinations of
different NHR agonist drugs with additive beneficial (or, con-
versely, deleterious) effects on experimental (and perhaps
human) NAFLD can be discovered using the approaches
described here [49]. For example, obeticholic acid, like Pio,
was also recently reported to have efficacy in human NAFLD
[50]. Thus, future assessments of the combinatorial effects of
Pio and obeticholic acid on transcriptional regulation and
liver disease in experimental NAFLD models might inform
consideration of new NHR-agonist combination interven-
tion trials for this increasingly prevalent disease.
Pio has previously been reported to improve hepatic
mitochondrial dysfunction in an in vivo NAFLD mouse
model [22]. Although its effects on hepatic mitochondrial
protein expression were not examined in that study, other
Table 3: Gene set analysis∗ on RXR ChIP-Seq data from Pio-treated vs. Pio-untreated WT or KO mice on control or HFD (as designated).
Gene set name (# in Hallmark set) Description Overlap q value
(a) Induced by Pio in WT mice on control diet
OXIDATIVE_PHOSPHORYLATION [200]




A subgroup of genes regulated
by MYC - version 1 (v1).
40 2.33e-26
ADIPOGENESIS [200]
Genes upregulated during adipocyte
differentiation (adipogenesis).
31 3.41e-17
ESTROGEN_RESPONSE_LATE [200] Genes defining late response to estrogen. 24 5.47e-11
FATTY_ACID_METABOLISM [158]
Genes encoding proteins involved in
metabolism of fatty acids.
21 1.34e-10
MTORC1_SIGNALING [200]








Genes upregulated during unfolded
protein response.
16 8.78e-9
ESTROGEN_RESPONSE_EARLY [200] Genes defining early response to estrogen. 19 2e-7
DNA_REPAIR [150] Genes involved in DNA repair. 16 4.31e-7
(b) Induced by Pio in WT mice on HFD
OXIDATIVE_PHOSPHORYLATION [200]








Genes upregulated during adipocyte
differentiation (adipogenesis).
20 2.72e-12
ESTROGEN_RESPONSE_LATE [200] Genes defining late response to estrogen. 15 1.22e-7
(c, d) Suppressed by Pio in WT mice on control or HFD
No overlaps found.
(e, f, g, h) Induced or suppressed by Pio or HFD in KO mice in presence or absence of HFD or Pio
No overlaps found.
∗Using the Broad Institute platform with the Hallmark gene set platform to identify the top 10 categories with p ≤ 1e−6 (see text for details).
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investigations have shown that Pio stimulates mitochondrial
biogenesis by upregulating specific PGC1α-regulated target
gene expression in extrahepatic tissues [51–53]. Those obser-
vations, together with the data reported here showing that
Pio broadly induces liver PPARγ-dependent RXR binding
and hepatic expression of many nuclear genes encoding
mitochondrial proteins (Figure 6(b)), implicate such regula-
tion as a plausible mechanism by which Pio exerts its
beneficial metabolic effects. However, older studies have par-
adoxically reported that Pio and other TZDs inhibit hepato-
cellular mitochondrial function in vitro [54–56]. Thus,
further investigations are required.
One limitation of the studies reported here is that the
HFD regimen employed here (60% of calories from fat) had
relatively modest metabolic effects. Although hepatic steato-
sis was not significantly increased by this regimen, the
HFD-fed mice studied here did gain more weight over the
experimental timecourse and display higher adiposity and
serum FFA levels at the experimental endpoint, compared










































































































Figure 6: BETA Analyses of Pio’s Effects on Mitochondrial Gene Expression - (a) Venn diagram analysis depicting genes identified by BETA
as most likely to be regulated by Pio-induced effects on liver RXR-DNA binding in WT mice on control versus HFD. (Input RXR-liver DNA
binding data from the KO mice was insufficient to execute BETA.) (b) Nuclear genes encoding mitochondrial proteins identified by BETA as
likely to be Pio-induced by PPARγ-dependent effects on liver RXR-DNA binding (genes in orange were identified from analyses of mice on
control diet; those in blue from analyses of mice on HFD; and those in black from analyses of mice on either diet). ∗The mitochondria
illustration is adapted from an image freely available in the public domain at https://commons.wikimedia.org/wiki/File:Mitochondrial_
electron_transport_chain%E2%80%94Etc4.svg.
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the literature describing results with this model are consistent
with the data reported here and also note the correlation
between duration-of-HFD-exposure and development of
steatosis. Despite this limitation, our data nevertheless
demonstrate a PPARγ-dependent modifying influence of
this diet on Pio-regulated changes in hepatic gene expres-
sion, including Pio’s effects on mitochondrial gene expres-
sion (Figure 6(b)). Moreover, our data also indicate that
the HFD regimen used here does not detectably alter liver
RXR-DNA binding patterns, suggesting that the HFD
effects on Pio-regulated hepatic gene expression reported
here are either independent of such RXR-DNA binding
or dependent on extrahepatic effects of HFD, Pio, or both
(as additionally considered below). Future analyses com-
paring Pio’s transcriptional effects here to those in mice
given a “Western” or “methionine-choline deficient” diet,
each of which induces more severe NAFLD phenotypes,
might offer additional insights about these consideration.
A second limitation is that only male mice were studied
here. This strategy emerged from feasibility constraints
while optimizing the experimental and analytical method-
ologies required for these experiments. Of note, a recent
study reported sexually dimorphic RXR-liver DNA binding
and hepatic expression of specific metabolic genes [36].
Thus, with the feasibility of the approach employed here
now established, future investigations should investigate
sex-specific effects on Pio-induced, PPARγ-dependent
hepatic transcriptional regulation and the influence of diet
on such control. The results could have important impli-
cation for future human clinical trials testing Pio or other
NHR-binding drugs. A third caveat relates to the consider-
ations that these studies were limited to examination of
hepatic transcriptional regulation, despite well-known
extra-hepatic PPARγ-dependent (and independent) tran-
scriptional effects of Pio. Feasibility considerations also
influenced this approach. Nevertheless, inclusion of assess-
ments of liver RXR-DNA binding and analyses of liver-
specific PPARγ KO mice, here, has novel implications
for consideration of direct versus indirect hepatic effects
of Pio. For example, our observation that Pio does not
alter liver RXR-DNA binding in liver-specific PPARγ KO
mice leads us to conclude not only that Pio-induced
changes in RXR-liver DNA binding depend on hepatocel-
lular PPARγ expression but also that Pio-induced hepatic
transcriptional effects in KO mice result, at least in part,
from regulation by extrahepatic signals. Nevertheless,
Table 4: Gene set analysis∗ on BETA data from WT Pio-treated vs. Pio-untreated mice on control or HFD (as designated).
Gene set name (# in Hallmark set) Description Overlap q value
(a) Induced by Pio in WT mice on control diet
OXIDATIVE_PHOSPHORYLATION [200]




Genes encoding proteins involved in
metabolism of fatty acids.
25 9.9e-16
ADIPOGENESIS [200]




A subgroup of genes regulated
by MYC—version 1 (v1).
19 2.54e-8
(b) Induced by Pio in WT mice on HFD
OXIDATIVE_PHOSPHORYLATION [200]




A subgroup of genes regulated
by MYC - version 1 (v1).
15 5.89e-8
FATTY_ACID_METABOLISM [158]
Genes encoding proteins involved in
metabolism of fatty acids.
13 1.52e-7
(c) Suppressed by Pio in WT mice on control diet
UV_RESPONSE_UP [158]




Genes upregulated during unfolded protein
response, a cellular stress response related
to the endoplasmic reticulum.
17 1.66e-7
E2F_TARGETS [200]
Genes encoding cell cycle related targets
of E2F transcription factors.
21 8.05e-7
P53_PATHWAY [200] Genes involved in p53 pathways and networks. 21 8.05e-7
TNFA_SIGNALING_VIA_NFKB [200]
Genes regulated by NF-kB in response
to TNF (GeneID=7124).
21 8.05e-7
(d) Suppressed by Pio in WT mice on HFD
MYC_TARGETS_V1 [200]
A subgroup of genes regulated
by MYC—version 1 (v1).
17 4.45 e-8
∗Using the Broad Institute platform with the Hallmark gene set platform to identify the top 10 categories with p ≤ 1e−6 (see text for details).
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future studies could query relationships between and the
tissue-specific dependence of Pio’s hepatic and extrahe-
patic transcriptional effects by similar analyses of muscle
and adipose collected from the liver-specific PPARγ KO
mice studied here and of mice with extra-hepatic PPARγ
disruption. Hepatic mitochondrial activity could also be
assessed to evaluate the relationship between mitochon-
drial gene transcriptional regulation and function in
these models.
In conclusion, these analyses define Pio’s direct and indi-
rect effects on hepatic transcriptional regulation and impli-
cate diet as a modifier of those effects. They also show that
Pio broadly induces liver PPARγ-dependent hepatic expres-
sion of nuclear genes encoding mitochondrial proteins and
that diet also impacts that regulation. Of note, only c.a. half
of the subjects in the PIVENS trial showed drug-induced
improvements in NAFLD [9]. Our data raise the provocative
possibility that dietary effects on Pio-induced, liver PPARγ-
dependent hepatic expression of nuclear genes encoding
mitochondrial proteins might correlate with or even mediate
the variable efficacy of Pio in that trial. This consideration is
important because of the current epidemic of NAFLD
together with the paucity of FDA-approved drugs for treat-
ment of that condition. Indeed, based on those circum-
stances, the American Association for the Study of Liver
Disease (AASLD) and the European Association for the
Study of the Liver (EASL) have recommended that Pio be
considered in patients with biopsy-proven NASH taking into
account the risks [57]. Finally, mitochondrial gene expres-






















































NHR-RXR specific response elements
AGGTCA-spacer-AGGTCA
(c)
Figure 7: Distinct effects of Pio vs other NHR agonists. (a, b) Venn diagrams depicting (a) distinct effects of PIO (reported here) versus
obeticholic acid (Obe, reported in [45]) on the hepatic transcriptome in mice and (b) PIO (reported here) versus the LXRα agonist
T0901317 (reported in [35]) on the liver RXR cistrome. (c) Hypothetical model illustrating how different NHR-binding drugs might exert
unique effects on transcriptional regulation by competing for RXR-binding, with different NHR-RXR heterodimers displaying distinct
affinities for specific NHR-RXR DNA response elements based on spacer length and other factors (e.g., RXR-ligand binding by 9-cis-
retinoic acid). RXR homo-dimerization also affects transcription. ∗The cell nucleus illustration is adapted from vectors from http://www
.servier.com and licensed under the Creative Commons Attributions Unported license.
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human diseases [58–60]. Thus, the data reported here might
ultimately have broader relevance for future efforts to
develop NHR-based therapies for human diseases.
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The ChIP- and RNA-Seq data used to support the findings of
the studies reported here have been deposited in NCBI’s
Gene Expression Omnibus (GEO [34]) and will be made
accessible to the public as GEO series records GSE137820
(for ChIP-Seq data) and GSE140607 (for RNA-Seq data) at
the time this manuscript is accepted for publication. In addi-
tion, excel spreadsheets summarizing the results of the RNA-
Seq, RXR-ChIP, and BETA data analyses (i.e., for RNA-Seq,
lists of differentially expressed genes with fold change, confi-
dence interval, p and q value; for ChIP-Seq, lists of differen-
tially RXR-bound genes, with fold difference, q value, and
genomic site of binding; for BETA, gene name, rank, and
rank product) are provided in Supplementary Table S2.
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Supplementary Materials
Supplementary Figure S1: immunoblot analysis of the anti-
RXRα/β/γ (Santa Cruz sc-774) antibody that was used for
the ChIP-Seq studies reported here. The predominant detect-
able band in all liver samples (i.e., from control, Pio-treated,
HFD-treated, and HFD-Pio-treated mice) is ~53 kDa band,
which is the molecular weight of RXR, and accounts for
>50% of the total detected signal in each lane (average 81%
across all samples, as assessed using Odyssey Infrared Imag-
ing System Application Software Version 3.0.21, Licor Bio-
sciences), which is consistent with the ENCODE and
modENCODE guidelines [37, 61]. Supplementary Figure
S2: the left panel shows initial body weights (in grams) of
WT and KO mice (as designated) that were subsequently
assigned to the indicated experimental groups (no significant
differences between groups). The right panel shows a sum-
mary of initial body weights in all WT versus all KO mice
(p < 0:05). Supplementary Figure S3: summary of RT-qPCR
based analyses of exemplar genes whose RNA-Seq based pat-
terns of expression are depicted in Figure 3. Supplementary
Table S1: gene-specific oligonucleotide primers for RT-
qPCR. Supplementary Table S2: RNA-Seq, ChIP-Seq, and
BETA Analyses Results—see excel Table S2. This excel
spreadsheet contains (A) List of Experimental Groups, (B) a
merged summary of all RNA-Seq differential expression
analyses, summaries of differentially RXR-bound peaks iden-
tified by ChIP-Seq analyses of liver samples from wildtype
(C) Pio vs. control or (D) HFD-Pio-treated vs. HFD-treated
mice, and (E) summary lists from BETA analyses of RNA-
and ChIP-Seq data from comparisons of Pio vs. control and
HFD-Pio vs. HFD (including rank, Gene name, and rank
product). Supplementary Table S3: GAGE results—see excel
Table S3: this excel spreadsheet contains GAGE gene set
expression perturbation test results for all comparisons
between groups conducted by Limma. Log 2 fold changes
of all genes within specific gene sets were compared to all
those outside those sets using Student’s t-tests. Results are
reported as mean log 2 fold-change, p value, and
Benjamini-Hochberg FDR adjusted p value. Supplementary
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Table S4: gene set analysis on RNA-Seq data from HFD vs.
control diet-treated WT mice: these tables were generated
using the Broad Institute platform with the Hallmark gene
set platform to identify the top 10 categories with p ≤ 1e−6
(see text for additional details). Supplementary Table S5:
gene set analysis∗ on RNA-Seq data from HFD vs. control
diet-treated KO mice: these tables were generated using the
Broad Institute platform with the Hallmark gene set platform
to identify the top 10 categories with p ≤ 1e−6 (see text for
additional details). (Supplementary Materials)
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